Sarepta Therapeutics (SRPT) Receivables (2010 - 2026)
Sarepta Therapeutics' quarterly Receivables came in at $531.2 million in Q1 2026, down 25.66% year-on-year from $714.6 million in Q1 2025, and up 5.75% quarter-over-quarter from $502.3 million in Q4 2025.
Sarepta Therapeutics has reported Receivables for 17 years, with the latest figure at $531.2 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables fell 25.66% year-over-year to $531.2 million; the trailing twelve-month figure through Mar 2026 stood at $531.2 million (down 25.66% YoY), and the FY2025 full-year result was $502.3 million, down 21.09% from the prior year.
- Receivables for Q1 2026 stood at $531.2 million, up from $502.3 million in the prior quarter.
- The five-year high for Receivables was $714.6 million in Q1 2025, with the low at $195.9 million in Q1 2022.
- Average Receivables over 5 years is $411.9 million, with a median of $408.9 million recorded in 2024.
- Year-over-year, Receivables jumped 97.36% in 2023 and decreased 25.66% in 2026.
- Tracing SRPT's Receivables over 5 years: stood at $217.9 million in 2022, then jumped by 97.36% to $430.1 million in 2023, then soared by 48.0% to $636.6 million in 2024, then fell by 21.09% to $502.3 million in 2025, then rose by 5.75% to $531.2 million in 2026.
- The last three Receivables figures came in at $531.2 million (Q1 2026), $502.3 million (Q4 2025), and $524.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 13.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 4.15 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.00 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.73 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 883.96 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn | 531.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 531.20 Mn |
| Dec 31, 2025 | 502.30 Mn |
| Sep 30, 2025 | 524.40 Mn |
| Jun 30, 2025 | 600.60 Mn |
| Mar 31, 2025 | 714.60 Mn |
| Dec 31, 2024 | 636.59 Mn |
| Sep 30, 2024 | 500.92 Mn |
| Jun 30, 2024 | 379.90 Mn |
| Mar 31, 2024 | 408.90 Mn |
| Dec 31, 2023 | 430.13 Mn |
| Sep 30, 2023 | 354.26 Mn |
| Jun 30, 2023 | 265.40 Mn |
| Mar 31, 2023 | 285.84 Mn |
| Dec 31, 2022 | 217.94 Mn |
| Sep 30, 2022 | 223.40 Mn |
| Jun 30, 2022 | 230.25 Mn |
| Mar 31, 2022 | 195.90 Mn |
| Dec 31, 2021 | 153.01 Mn |
| Sep 30, 2021 | 178.42 Mn |
| Jun 30, 2021 | 145.22 Mn |
| Mar 31, 2021 | 133.30 Mn |
| Dec 31, 2020 | 135.54 Mn |
| Sep 30, 2020 | 138.70 Mn |
| Jun 30, 2020 | 112.89 Mn |
| Mar 31, 2020 | 123.32 Mn |
| Dec 31, 2019 | 90.41 Mn |
| Sep 30, 2019 | 68.03 Mn |
| Jun 30, 2019 | 56.19 Mn |
| Mar 31, 2019 | 51.80 Mn |
| Dec 31, 2018 | 50.96 Mn |
| Sep 30, 2018 | 48.60 Mn |
| Jun 30, 2018 | 42.06 Mn |
| Mar 31, 2018 | 38.92 Mn |
| Dec 31, 2017 | 30.18 Mn |
| Sep 30, 2017 | 23.82 Mn |
| Jun 30, 2017 | 17.79 Mn |
| Mar 31, 2017 | 13.21 Mn |
| Dec 31, 2016 | 6.45 Mn |
| Sep 30, 2016 | 3.99 Mn |
| Jun 30, 2016 | 3.98 Mn |
| Mar 31, 2016 | 3.99 Mn |
| Dec 31, 2015 | 7.95 Mn |
| Sep 30, 2015 | 2.73 Mn |
| Jun 30, 2015 | 2.42 Mn |
| Mar 31, 2015 | 2.42 Mn |
| Dec 31, 2014 | 4.82 Mn |
| Sep 30, 2014 | 5.86 Mn |
| Jun 30, 2014 | 9.13 Mn |
| Mar 31, 2014 | 13.35 Mn |
| Dec 31, 2013 | 5.93 Mn |
| Sep 30, 2013 | 10.92 Mn |
| Jun 30, 2013 | 6.89 Mn |
| Mar 31, 2013 | 10.35 Mn |
| Dec 31, 2012 | 7.91 Mn |
| Sep 30, 2012 | 4.95 Mn |
| Jun 30, 2012 | 11.40 Mn |
| Mar 31, 2012 | 5.14 Mn |
| Dec 31, 2011 | 5.73 Mn |
| Sep 30, 2011 | 4.27 Mn |
| Jun 30, 2011 | 10.89 Mn |
| Dec 31, 2010 | 3.22 Mn |